CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
NK 细胞：血液系统恶性肿瘤中开发嵌合抗原受体抗癌细胞的新兴有前景来源
英文原题：Natural killer cells: a new promising source for developing chimeric antigen receptor anti-cancer cells in hematological malignancies.
查看英文原题
Natural killer cells: a new promising source for developing chimeric antigen receptor anti-cancer cells in hematological malignancies.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
近年来，CAR-T 细胞治疗取得显著进展，在血液系统恶性肿瘤中显示出令人鼓舞的治疗结局。然而，伴随这些进展，该技术广泛应用仍受到一些局限和挑战阻碍。近期，CAR-NK细胞在癌症治疗中受到关注；与CAR-T 疗法相比，其用于靶向异体细胞具有一项重要优势，即无需进行HLA配型。本综述旨在探讨CAR-NK细胞疗法的优势、制备策略，以及阻碍其应用于血液系统恶性肿瘤实验研究和临床试验的挑战与局限。
展开英文摘要原文
In recent times, the application of CAR-T cell treatment has significantly progressed, showing auspicious treatment outcomes in hematologic malignancies.
However, along with these advances, certain limitations and challenges hurdle the widespread utilization of this technology. Recently, CAR-NK cells have gained attention in cancer treatment, as this approach has an important advantage over CART therapy (i. e. no need for HLA matching) for targeting foreign cells. This review aims to explore the benefits of CAR NK cell therapy, and generation strategies, as well as the challenges and limitations hindering the application of CAR NK cells in experimental studies and trials on hematologic malignancies.
论文信息
- 作者
- Mousavi S、Khazaee-Nasirabadi MH、Seyedmehdi MS、Bazi A、Mirzaee Khalilabadi R
- 第一作者单位
- Department of Hematology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.Iran
- 通讯作者单位
- Department of Hematology and Medical Laboratory Sciences, Faculty of Allied Medicine, Kerman University of Medical Sciences, Kerman, Iran.Iran
- 文献类型
- 综述
- 期刊
- Leukemia & lymphoma2025 Apr
- 原文标识
- PubMed 39656564 · DOI 10.1080/10428194.2024.2438802